Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Abstract Background Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab p...

Full description

Bibliographic Details
Main Authors: Miguel Quintela-Fandino, Esther Holgado, Luis Manso, Serafin Morales, Begoña Bermejo, Ramon Colomer, Juan V. Apala, Raquel Blanco, Manuel Muñoz, Eduardo Caleiras, Vega Iranzo, Mario Martinez, Orlando Dominguez, Javier Hornedo, Lucia Gonzalez-Cortijo, Javier Cortes, Ariadna Gasol Cudos, Diego Malon, Antonio Lopez-Alonso, María C. Moreno-Ortíz, Silvana Mouron, Santos Mañes
Format: Article
Language:English
Published: BMC 2020-11-01
Series:Breast Cancer Research
Subjects:
Durvalumab
Bevacizumab
HER2-negative breast cancer
Vascular normalization
Immuno-priming
Online Access:http://link.springer.com/article/10.1186/s13058-020-01362-y

Internet

http://link.springer.com/article/10.1186/s13058-020-01362-y

Similar Items